Sign In

James C. Mulloy PhD


James C. Mulloy PhD
Asst ProfessorCollege of Medicine--UCjames.Mulloy@cchmc.org
S7.603/ML 7013 3333 Burnet Ave Cincinnati OH 45229
Phone:513-636-1844Fax: 513-636-3768
  • Molecular Biology and Cancer Genetics

General Research Interest

Leukemia, hematopoiesis, transcription factor activity, epigenetics, xenograft leukemia model, survival signaling in leukemia

Research Description

Research in the Mulloy Laboratory focuses on using human hematopoietic stem/progenitor cells (HSPC) to model leukemia. The prevailing theory is that acute myeloid leukemia is a stem cell disease. We believe the technology and expertise are now available that permit us to use primary human HSPC to dissect the stepwise progression of human AML. As a proof of principal, we have expressed the AML1-ETO fusion protein in human CD34+ cells by retroviral transduction and characterized the genetic and functional alterations that occur due to expression of this oncogene These studies have recently been extended to two additional oncogenes, CBFb-MYH11 and MLL-AF9.

Transinstitutional Work

The Mulloy lab is currently collaborating with the laboratory of Dr. Guido Marcucci, using constitutively active mutants of the c-kit protein in cooperative leukemia initiation studies with the AML1-ETO and CBFb-MYH11 oncoproteins.

Current Publications

  • Bell-Horwath TR, Vadukoot AK, Thowfeik FS, Li G, Wunderlich M, Mulloy JC, Merino EJNovel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia.Bioorg Med Chem Lett 23(10) 2951-4 5/15/2013
  • Wunderlich M, Mizukawa B, Chou FS, Sexton C, Shrestha M, Saunthararajah Y, Mulloy JCAML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.Blood 121(12) e90-7 3/21/2013
  • Goyama S, Mulloy JCMaking healthy stem cells: the new role of TPO.Cell Stem Cell 12(1) 8-9 1/3/2013
  • Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD, Chen JMiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.Proc Natl Acad Sci U S A 109(47) 19397-402 11/20/2012
  • Zhang Y, Yan X, Sashida G, Zhao X, Rao Y, Goyama S, Whitman SP, Zorko N, Bernot K, Conway RM, Witte D, Wang QF, Tenen DG, Xiao Z, Marcucci G, Mulloy JC, Grimes HL, Caligiuri MA, Huang GStress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells.Blood 120(5) 1118-29 8/2/2012
  • Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, Goyama S, Mizukawa B, Shen S, Marcucci G, Mulloy JCThe thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO.Blood 120(4) 709-19 7/26/2012
  • Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A, Mulloy JC, Oliva EN, Cuzzola M, Starczynowski DTCytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.Blood 120(4) 858-67 7/26/2012
  • Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, Wang Y, Neilly MB, Jin J, Wei M, Lu J, Valk PJ, Delwel R, Lowenberg B, Le Beau MM, Vardiman J, Mulloy JC, Zeleznik-Le NJ, Liu PP, Zhang J, Chen JmiR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.Nat Commun 3 688 2/21/2012
  • Mizukawa B, Wei J, Shrestha M, Wunderlich M, Chou FS, Griesinger A, Harris CE, Kumar AR, Zheng Y, Williams DA, Mulloy JCInhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia.Blood 118(19) 5235-45 11/10/2011
  • Ng KP, Ebrahem Q, Negrotto S, Mahfouz RZ, Link KA, Hu Z, Gu X, Advani A, Kalaycio M, Sobecks R, Sekeres M, Copelan E, Radivoyevitch T, Maciejewski J, Mulloy JC, Saunthararajah Yp53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.Leukemia 25(11) 1739-50 11/1/2011
  • Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CRRNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.Nature 478(7370) 524-8 8/3/2011
  • Goyama S, Mulloy JCMolecular pathogenesis of core binding factor leukemia: current knowledge and future prospects.Int J Hematol 94(2) 126-33 8/1/2011